APOBEC3B mediated the resistance to cisplatin in non-small cell lung carcinoma
10.3760/cma.j.cn431274-20200506-00565
- VernacularTitle:APOBEC3B介导非小细胞肺癌顺铂耐药
- Author:
Yongsheng CHEN
1
;
Danqing HUANG
;
Yixue GU
;
Min DENG
;
Huaping ZHOU
;
Guopei ZHENG
;
Zhimin HE
Author Information
1. 广州医科大学附属肿瘤医院肿瘤研究所 510095；广州市恶性肿瘤转化医学重点实验室 510095
- From:
Journal of Chinese Physician
2020;22(5):662-666,673
- CountryChina
- Language:Chinese
-
Abstract:
Objective:APOBEC3B (A3B) is an important member of the apolipoprotein B mRNA editing enzyme catalytic polypeptide (APOBEC) family. The study aims to investigate the relationship between A3B expression and prognosis as well as resistance to cisplatin in non-small cell lung cancer (NSCLC).Methods:Real-time quantitative polymerase chain reaction (qRT-PCR) was used to analysis the A3B mRNA expression in 40 NSCLC tissues; Kaplan Meier plotter was used to analyse the correlation between A3B expression and clinical prognosis; in addition, the knock-down A3B expression cell line in human lung adenocarcinoma cell A549 was constructed; MTS and plate cloning experiment were performed to observe the changes in cell cisplatin sensitivity, and γ-H2AX immunofluorescence was used to quantitate the DNA damage.Results:Compared with adjacent tissues, A3B was highly expressed in NSCLC tissues (27/40). Kaplan Meier plotter analysis showed that A3B expression was positively correlated with NSCLC overall survival (OS) [adenocarcinoma: HR=0.64(0.47-0.86), P=0.002 6; squamous cell carcinoma: HR=0.77(0.59-1.01), P=0.006]. Cell-based studies showed that the knock-down A3B expression contributed to sensitivity to cisplatin in A549 cells. Conclusions:A3B mediates the sensitivity of lung cancer to cisplatin. This effect may partly explain why NSCLC patients with high A3B expression have a better prognosis.
